EMAIL THIS PAGE TO A FRIEND

Journal of ethnopharmacology

Prevention of pulmonary fibrosis with salvianolic acid a by inducing fibroblast cell cycle arrest and promoting apoptosis.


PMID 25102244

Abstract

Danshen (Salvia miltiorrhiza Bunge) is widely used in traditional Chinese medicine (TCM), often in combination with other herbs, to treat a diversity of ailments. More recent studies have focused on its possible roles in the treatment of respiratory diseases (pneumonia and pulmonary fibrosis) and found that it has pharmacological activity that protects pulmonary morphology and function. However, the mechanism underlying this activity has not yet been clarified. The purpose of this study was to investigate the anti-pulmonary fibrosis effects exerted by salvianolic acid A (SAA), the ingredient responsible for the pharmacological activity of Danshen, and the underlying mechanisms. Bleomycin (BLM)-induced rat pulmonary fibrosis was used to evaluate the antifibrotic role of SAA, and fibroblast cells were used to study the mechanism involved. BLM-treated rats exhibited increased alveolar wall thickness and collagen deposition in lung tissues, but these pathologies were greatly attenuated by daily administration of SAA. We also found that SAA significantly inhibited the proliferation, adhesion and migration of fibroblasts in vitro. This was partly due to a strong induction of cell cycle arrest and apoptosis upon SAA treatment. Consistent with these phenotypes, we observed decreased expression of the cell cycle-related proteins cyclin D1, cyclin E1, and cyclin B1, and increased expression of p53 and p21 in SAA-treated cells. In addition, the anti-apoptotic Bcl-2 protein decreased in a dose-dependent manner, while cleaved caspase-3 protein increased upon SAA treatment. These results suggest that the alleviation of rat pulmonary fibrosis by SAA is due to the inhibition of fibroblast proliferation and induction of apoptosis, which occurs mainly through p53-dependent growth arrest and apoptosis. We suggest that SAA should be considered as a potential novel therapeutic agent for the treatment of fibrotic lung diseases.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2502098
Anti-PCNA antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2502099
Anti-PCNA antibody produced in goat, affinity isolated antibody, buffered aqueous solution
AV03018
Anti-PCNA antibody produced in rabbit, IgG fraction of antiserum
HPA030521
Anti-PCNA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab1
HPA030522
Anti-PCNA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab2
HPA030523
Anti-PCNA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab3
SAB2701819
Anti-PCNA antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB4502103
Anti-PCNA antibody produced in rabbit, affinity isolated antibody
WH0005111M2
Monoclonal Anti-PCNA antibody produced in mouse, clone 1G7, purified immunoglobulin, buffered aqueous solution
SAB1404178
Monoclonal Anti-PCNA antibody produced in mouse, clone S1, purified immunoglobulin, buffered aqueous solution
SAB4100556
Monoclonal Anti-PCNA antibody produced in mouse, clone PCNA -A509, culture supernatant
PLA0079
Rabbit anti-PCNA Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.
PLA0080
Rabbit anti-PCNA Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.